LBA23 ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2- ABC) with aggressive disease criteria

J. De la Haba Rodriguez, J. Cortés, Serena Di Cosimo, I. Blancas López-Barajas, Silvia Patricia Cortez Castedo, A. López, Elena López-Miranda, H. Pla Juher, C.R. Albacar Miro, J. Ponce, V. Carañana Ballerini, L. París Bouzas, M. Valero Arbizu, Manuel Ruíz Borrego, Vega Iranzo, A. Garrido, Daniel Alcalá-López, Leonardo Mina, J.J. Garcia Mosquera, A. Llombart Cussac